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Purpose: Cardiovascular disease (CVD) risk assessment is an important strategy for the preven-
tion of CVD. Pharmacists play an important role in CVD risk assessment and management
(CVDRAM). Our previous study identified gaps in knowledge among community pharmacists
for the provision of CVDRAM services as assessed through patient simulation. Therefore, our
objectives were: a) to develop and evaluate an educational program on CVD risk assessment for
community pharmacists, b) to assess the knowledge and skills of participating pharmacists in
assessing and managing CVD risk before and after enrolling in the educational program and c) to
explore pharmacists’ satisfaction and perceived effectiveness of the educational program.
Methods: Using a blended learning instructional approach, the educational program for
a subset of 25 community pharmacists recruited from our previous study consisted of two
face-to-face workshops, and an online 5-module course on CVD risk factors such as
hyperlipidemia, hypertension, diabetes, obesity, and smoking cessation based on principles
of adult learning. A repeated measures study design was utilized by measuring participants’
knowledge on pre- and post-questionnaires and an objective structured clinical examination
(OSCE) at the conclusion of the educational program was also used to assess its impact on
the knowledge and skills of community pharmacists in the provision of CVD risk assessment
and management (CVDRAM) services. The knowledge questionnaire was completed by 23
pharmacists while the OSCE was completed by 8 pharmacists. In addition, a survey assessed
the pharmacists’ level of satisfaction with the educational program.
Results: At the conclusion of the educational program, the participating pharmacists achieved
knowledge and skills for the provision of CVDRAM services. Knowledge scores in relation to
CVDRAMsignificantly improved after the educational program [out of a maximum of 20 points,
the median (interquartile range) = 9 (7–9) at pre- vs 12 (12–13) at post-educational program],
p<0.001. On the OSCE, the median (interquartile range) scores for Stations 1 and 2 were 66
(63–71) and 71 (67–76), respectively. Out of the 21 pharmacists that completed the satisfaction
survey, 71% were very satisfied and 29% were satisfied with the educational program.
Conclusion: The educational program improved pharmacists’ knowledge and skills for the
provision of CVDRAM services.
Keywords: community pharmacists, cardiovascular disease risk assessment, educational
program, pharmacists’ preparedness, evaluation
Introduction
Cardiovascular disease (CVD) is the most common cause of death globally.1 In Qatar,
CVD was responsible for 24% of the total deaths reported in 2013.2,3 Furthermore,
reports from the World Health Organization (WHO) have indicated high prevalence
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rates of CVD risk factors in Qatar, such as tobacco smoking,
hypertension, obesity, dyslipidemia and diabetes.2,4,5 Despite
considerable evidence-based knowledge about risk factor
management, CVD remains the leading cause of disability
and premature death throughout the world.4 Consequently,
WHO recommends prevention2,3 of CVD through early
detection and management of individuals who are at a high
risk of developing CVDs.1 This necessitates the need for
development and implementation of highly accessible
screening programs to assess and manage cardiovascular
risk. A precise estimate of the absolute risk for developing
a first CVD event using tools such as the Framingham Risk
Score is preferred when making prevention and treatment
recommendations.4,5
Community pharmacists are one of the most accessible
healthcare professionals that have been shown to play an
effective role in screening and reducing the severity of estab-
lished risk factors, as well as in the primary prevention and
management of CVD.6–9 There is sufficient evidence for
improved clinical outcomes when pharmacists are involved
in the assessment of cardiovascular risk as outlined below.
A recent large multi-centered controlled trial involving 56
community pharmacies in Canada that enrolled 723 patients
has shown a 21% reduction in risk for CVD events after 3
months among patients that were under the care of pharma-
cists with competence in providing CVD risk assessment and
management (CVDRAM) services compared to pharmacists
providing usual care.10 A pilot study of 12 pharmacists in
Australia that provided care for 67 participants showed
a significant 25% proportional risk reduction in overall
CVD risk.11 A meta-analysis of 30 randomized controlled
trials of pharmacist-directed care or -collaborative care
resulted in significant improvements in systolic and diastolic
blood pressure, total cholesterol, low-density lipoprotein –
cholesterol and reduction in smoking.12
Despite this evidence, pharmacists in Qatar appear to
be largely under-utilized and poorly integrated into pri-
mary care teams. In a recent study in Qatar, community
pharmacists perceived a lack of education as the top bar-
rier in the provision of services which promote cardiovas-
cular health.13 In another recent study in Qatar, researchers
worked with standardized patients (SPs) to assess the
knowledge and skills of community pharmacists in the
provision of CVD risk assessment services.14 The results
of the study indicated a gap in the pharmacists’ compe-
tence for the provision of CVDRAM services.
Currently, community pharmacists in the State of Qatar
are primarily involved in dispensing medications and
providing counseling. The State of Qatar has prioritized
health promotion as part of its National Health Strategy.
Consequently, there are plans to introduce enhanced and
advanced pharmacy services managed by community phar-
macists. It is therefore important to assess their baseline
knowledge and skills to provide further education to suc-
cessfully implement such services. No studies to date have
reported the development and evaluation of educational
programs for capacity building on CVD risk assessment
among practicing pharmacists. The aim of the current
study is to 1) develop and implement a CVD risk assess-
ment educational program for community pharmacists; 2) to
objectively evaluate the impact of the educational program
on the knowledge and skills of participating pharmacists
and 3) to assess the participant’s perception of the educa-
tional program. We believe that this is a novel approach in
Qatar and the materials developed will be updated and used
in the future to train a large cohort of community pharma-
cists to advance their skills and knowledge.
One of the long-term goals of this study is to imple-
ment the provision of CV risk assessment services by
community pharmacists in Qatar to improve patients' out-
comes. Pharmacist intervention through CV risk assess-
ment has been shown to reduce absolute risk of developing
CV events.10,11 Importantly, recent studies in the Middle
East region have shown community pharmacist interven-
tions to reduce overall Atherosclerotic Cardiovascular
Disease or Framingham risk score15,16 suggesting feasibil-
ity of such models in Qatar. Our previous study has shown
that community pharmacists in Qatar are willing to learn
and provide CVDRAM services.14 Therefore, this educa-
tional program can prove to be useful for the implementa-
tion of such services in Qatar.
Methods
Study Participants
Fifty pharmacists working in various community pharma-
cies in urban areas in the State of Qatar, whose prepared-
ness in the provision of CVDRAM had been assessed
during an interaction with a trained SP in our previous
study,14 were invited to participate in this CVDRAM edu-
cational program. Twenty-five pharmacists participated in
our current educational program.
Educational Program Development
A team of two pharmacists and a physician from the
College of Pharmacy designed this educational program.
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Several international guidelines were used to develop the
content of this program,2,17-20 which was delivered in
a blended format consisting of two face-to-face workshops
that lasted 3 hrs each, complemented by an online course
developed using Articulate 360® software (Articulate
Storyline 360, 2018).21 Appendix 1 provides a detailed
outline of the educational program.
In the first workshop, participants were introduced to
the role of community pharmacists in CVD risk assess-
ment. CVD risk factors such as hyperlipidemia, hyperten-
sion, diabetes, obesity, and smoking cessation and
approaches to the provision of CVDRAM services in
community pharmacies were briefly reviewed. Following
the first workshop, participants were given access to the
web-based course which consisted of 5 learning modules,
one for each of the preventable CVD risk factors men-
tioned above. Recommendations for pharmacological and
non-pharmacological management strategies, reference to
guidelines and additional resources were also provided.
The modules consisted of lectures that were recorded
directly into PowerPoint and converted into a web-based
course using the online platform provided by the course
builder software Articulate 360®. This software provides
a slide-based presentation with audio, guided quizzes, and
active hyperlinks. Prior to launching, the content was peer-
reviewed by experts in the field, and then circulated to two
pharmacy students. Experts and students provided feed-
back (in the form of reflection notes) on content, format
and overall impression of the course content. Their reflec-
tions were taken into considerations before launching the
final version of the online course. The workshop, web-
based learning modules and OSCE components were
accredited by the Qatar Council for Healthcare
Practitioners (QCHP) and participating pharmacists will
receive continuous education (CE) credits.
Box 1 describes the content of the final version of the
online course which continued to be available to partici-
pants beyond the study completion. Figure 1 shows
a screenshot of the web-based course.
The second face-to-face workshop was scheduled 1
month later, at which participants were introduced to the
steps in the implementation of CVDRAM services, and
provided them with the opportunity to have hands-on
training on the use of screening tools and point-of-care
(POC) devices appropriate for use in community pharma-
cies for assessing cardiovascular risk factors. In addition,
participants were trained on physical examination skills
necessary for CVD risk assessment such as measurement
of blood pressure, height, and weight. As recommended in
the guidelines on which this educational program was
based on2,17-20 primary health care professionals need to
convey information to patients in a way that allows them
to understand their cardiovascular risk and the potential
effects of lifestyle or pharmacological interventions, to
actively engage patients in shared decision-making. As
such, during the second workshop, participants also had
the opportunity to interact with SPs in order to enhance
their communication skills necessary for the provision of
CVDRAM services. The case scenarios on which the SPs
were trained and the SPs participating in this workshop
were the same as those utilized in our previous study.14
Video recordings of both workshops were also incorpo-
rated into the final version of the web-based course.
Assessment
An attempt was made to follow the Kirkpatrick’s evaluation
framework to assess the course outcomes. The Kirkpatrick’s
framework is a widely used evaluation model to assess the
effectiveness of CPD training and learning, a systematic
approach consisting of four levels of evaluation involving
examination of a course on multiple levels using different
data sources.22 This model has been applied by several other
researchers when developing courses in pharmacy practice
education.23–27 As such, the course used pre-/post-
questionnaires, interactive quizzes through the online mod-
ule, SPs, OSCE and a satisfaction survey in an attempt to
assess all 4 levels of Kirkpatrick’s evaluation framework.
Assessment of Participants’ Knowledge and Skills
Pre- and post-knowledge questionnaires were used to evaluate
the impact of the educational program on pharmacists’ knowl-
edge. A set of 13 multiple-choice questions and 7 true/false
questions were developed based on the content covered in the
Box 1 Content of the Final Version of the Online Course on
CVDRAM
Workshop 1: Introduction to cardiovascular risk assessment and
management
Learning module 1: Management of dyslipidemia
Learning module 2: Management of hypertension
Learning module 3: Glycemic control and vascular complications in
type 2 diabetes
Learning module 4: Weight and obesity management
Learning module 5: Smoking cessation
Workshop 2: Implementation of cardiovascular risk assessment
services
Dovepress Zolezzi et al







































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
workshops and in the 5 learning modules. The pre- and post-
knowledge questionnaires used as part of the assessment pro-
cess are provided as Appendix 2 and 3 respectively. The
questions focused on knowledge related to risk factors neces-
sary for estimating CVD risk, and on management guidelines
including pharmacological and non-pharmacological
approaches.
Upon completion of the educational program, compe-
tence in CVD risk assessment was assessed through an
objective structured clinical examination (OSCE) that was
offered to all participating pharmacists. The assessment con-
sisted of two stations facilitated by the same trained SPs who
participated in the second workshop. In Station 1, compe-
tence in performing physical examinations that are necessary
for assessing CVD risk factors was evaluated. In Station 2,
participants interacted with an SP and gathered relevant
information for estimating the SP’s absolute CVD risk. At
this station, participants also explained to the SP the meaning
of the estimated CVD risk in lay language, and drafted an
outline for lifestyle changes or pharmacological interventions
necessary to address the SP’s CVD risk. The participant’s
skills in this station were assessed using the same checklist
that was used in our previous study14 which evaluated 3
competencies: CVD risk assessment, CVD riskmanagement,
and participant’s engagement with the SP. A passing mark for
the OSCE was set at ≥65%. Thirty percent of the passing
mark was derived from the participant’s performance in
Station 1, and 70% from the participant’s performance in
Station 2. The OSCE checklist for stations 1 and 2 are
included as Appendix 4 and 5, respectively.
Satisfaction
A survey to assess the participants’ satisfaction and per-
ceived effectiveness of the educational program was
Figure 1 Screenshot of web-based course builder using Articulate 360® software. Representative screenshot of a course module developed using the Articulate 360®
software is shown.
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administered at the end of the educational program. Based
on literature review, a 5-point Likert scale ranging from
“Definitely yes”, “Some”, “Not sure”, “Not quite” to
“Definitely not” was used to evaluate the level of
satisfaction.28,29 For those who accepted to take part in
the OSCE, a list of open-ended questions was given at the
end asking them to reflect on various aspects of the educa-
tional program provided, about their OSCE experience,
what they felt about doing things differently at their prac-
tice sites, and which steps they felt they were more pre-
pared to take on the basis of what they had learnt through
their participation in this educational program.
Data Analyses
Data were entered into SPSS® v.22 (IBM, New York,
USA) to perform descriptive and inferential analyses.
The One-Sample-Kolmogorov–Smirnov test determined
that the data was “not normally” distributed. Therefore,
descriptive statistics are expressed as median and inter-
quartile range (IQR), and frequencies are expressed as
number (n) and percentage (%) to present the results
from pre- and post-questionnaires and from the satisfac-
tion survey, as appropriate. Statistical significance of
knowledge data before and after the educational program
presented in Tables 1 and 2 were compared using the
Wilcoxon signed-rank test and the McNemar Chi-square
test, respectively.
Ethical Compliance
Ethics approval for conducting this study was received
from Qatar University Institutional Review Board (QU-
IRB) in November 2016 (reference number: QU-IRB 672-
EA/16). The study was carried out in accordance with the
principles of the Declaration of Helsinki. The confidenti-
ality of participating pharmacists is maintained. Consent to
publish was obtained from the pharmacists as indicated in
the participant sheet and consent form.
Results
Out of the fifty pharmacists who participated in our pre-
vious study,14 50% (n=25) successfully completed the
educational program, of which 8 agreed to be evaluated
through the OSCE (32 % of participants who enrolled in
the educational program).
Impact of the Educational Program on
Pharmacists’ Knowledge and Skills
The knowledge and skills of participating pharmacists on
CVDRAM improved significantly after participation in the
educational program (Table 1). Out of a maximum of 20,
their knowledge scores improved from 9 (7–10) to 12
(12–13) [median (interquartile range)], p<0.001. Table 2
shows the number of pharmacists who had correct
responses to knowledge-based questions on the pre- and
post-questionnaires. As shown in this table, the number of
participating pharmacists answering each of the questions
correctly at post-educational program were significantly
higher than that at pre-educational program, except for
questions 1 (p<1.000), 2 (p<1.000) and 18 (p<0.022).
All pharmacists achieved a passing score in physical
examination and clinical decision making skills by obtaining
a passing mark in the OSCE (≥65%). The median (interquar-
tile range) score for Station 1 was 66 (63–71) out of 100. The
median score for Station 2 was 71 (67–76) out of 100. The
highest scores were 74 and 80 for Stations 1 and 2, respec-
tively. To determine whether a participating pharmacist
passed the OSCE, 30% weightage was given to scores from
Station 1 and 70% weightage to scores from Station 2 to
arrive at an aggregate of 65% minimum passing score.
Participant’s Perception of the
Educational Program
As illustrated in Figure 2, the majority of participants
indicated to be either satisfied or very satisfied with the
educational program. Percentage of pharmacists rating the
individual items of the satisfaction survey are shown in
Table 3. Participants who were evaluated through OSCE
reflected positively on their experience. Some of the com-
ments provided are outlined in Table 4.
Discussion
To the best of our knowledge, our study is novel in that
this educational program in CVDRAM was designed sys-
tematically after obtaining pharmacists’ perceptions,14
baseline knowledge and skills and is the first of its kind







score out of 20
9 (7–10) 12 (12–13) <0.001
Notes: †Analyses were performed for 23 pharmacists out of 25 since two of them
did not complete the post-training questionnaire. Knowledge score is the score
obtained on the written pre- and post-questionnaires that are 20 in number
including multiple choice questions and true/false type questions given in Table 3.
Abbreviations: IQR, Interquartile range; n, number of pharmacists.
Dovepress Zolezzi et al







































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
to be delivered in Qatar. The study describes in detail the
development of an educational program and its impact on
the knowledge and skills of practicing community phar-
macists to facilitate the provision of CVDRAM services.
Moreover, the knowledge and clinical skills were evalu-
ated using both written and OSCE formats.
Our CVDRAM course comprised a blended learning
strategy that included direct instructions, self-study
materials and multiple active learning components such
as face-to-face interactive workshops that provided parti-
cipants with the opportunity to familiarize with point of
care (POC) devices and practice their physical assessment
skills using SPs. To the best of our knowledge, this is the
first study to include several learning strategies in a single
educational program designed to train pharmacists on
CVD risk assessment. Workshops,30,31 simulation-based








1 MCQ: In adults 40–79 years of age who are free from atherosclerotic cardiovascular disease
(ASCVD), how often is it reasonable to estimate 10-year ASCVD risk?
6 (26) 5 (21.7) 1.000
2 MCQ: Which of the following is a general characteristic of the 2013 ACC/AHA guidelines
that is different than previous guidelines?
3 (13) 2 (8.7) 1.000
3 MCQ: The following are validated tools for estimating an individual’s risk for developing
clinically evident CVD, EXCEPT:
8 (34.8) 12 (52.8) 0.344
4 MCQ: Which of the following measures is needed for estimating CVD risk? 6 (26) 12 (52.8) 0.146
5 MCQ: All of the following conditions should be recorded when assessing CVD risk, EXCEPT: 14 (61) 23 (100) 0.004
6 MCQ: Men at age of 40 and women at age of 50 should be offered CVD risk assessment if
they have the following medical history, EXCEPT:
11 (47.8) 20 (87) 0.012
7 MCQ: Which of the following statements is INCORRECT in regards to the use of antiplatelet
therapy in primary prevention of CVD?
5 (21.7) 15 (65.2) 0.013
8 MCQ: Which of the following individuals are NOT suitable for starting HMG-CoA reductase
inhibitors (statin) therapy for primary prevention of CVD?
8 (34.8) 16 (70) 0.021
9 MCQ: Which of the following statin regimens is defined as high-intensity by the ACC/AHA
guidelines?
8 (34.8) 22 (95.7) 0.000
10 MCQ: Which of the following statements is INCORRECT in regards to obesity management
for patients at risk of developing CVD?
8 (34.8) 12 (52.8) 0.344
11 MCQ based on a provided case: Which of the following CVD risk reduction strategies is the
MOST suitable for Jane?
9 (39.1) 11 (47.8) 0.754
12 MCQ based on a provided case: Which of the following lifestyle management strategies are
NOT suitable for Jane?
1 (4.3) 9 (39.1) 0.008
13 MCQ based on a provided case: What other measurements and follow-up plan is
recommended for Jane?
1 (4.3) 5 (21.7) 0.219
14 T/F: High-intensity statin therapy generally results in an average LDL-C reduction of ≥50%
from the untreated baseline.
14 (61) 23 (100) 0.004
15 T/F: Sex and race/ethnicity are important risk factors for estimating the 10-year risk of a first
CV event in CVD-free populations.
19 (82.6) 22 (95.7) 0.375
16 T/F: Dietary Approaches to Stop Hypertension diet (aka DASH diet) is one of the
recommended patterns that helps in reducing blood pressure and lipids.
19 (82.6) 21 (91.3) 0.688
17 T/F: In the routine prevention of ASCVD, non-statin therapies provide similar risk-reduction
benefits compared to statin therapy.
14 (61) 18 (78.3) 0.344
18 T/F: β-blockers do not reduce CV events to the extent that has been proven with thiazide-
type diuretics, ACE inhibitors, ARBs, CCBs, or thiazide diuretics.
14 (61) 5 (21.7) 0.022
19 T/F: Women with polycystic ovary syndrome at age of 45 years are not candidates for CVD
risk assessment.
14 (61) 16 (70) 0.754
20 T/F: It is irrelevant to estimate the risk of CVD in a patient at age of 33 who has a low HDL-C
level of <27 mg/dL (0.7 mmol/L).
13 (56.5) 10 (43.5) 0.508
Notes: Analyses were performed for 23 pharmacists out of 25 since two of them did not complete the post-training questionnaire. n and % represent the number and
percentage of pharmacists, respectively, that answered each question correctly.
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training,32 direct instruction,33 use of SPs34,35 have been
shown to improve knowledge and skills of
pharmacists34,35 and students36 alike. The interaction
with trained SPs during the workshops and the continuous
availability of the workshop recordings incorporated into
the online course provided participants with the opportu-
nity to improve their communication skills and reduce
their apprehension when delivering patient education on
CVD risk and its management. Similar results were
obtained in a study which assessed the learning outcomes
when using a blended learning design to deliver
a communication course to pharmacy students.37 Lastly,
the study materials were made available throughout the
educational program using Articulate 360® and supported
the information delivered during the workshops. All of the
components of the educational program were in line with
advantages of blended learning courses previously
described.38 Other authors have also reported on the suc-
cessful use of earlier versions of this Articulate 360® web-
based software in pharmacy education.39,40
The educational program was particularly effective in
improving pharmacists’ knowledge on a number of









Total n=23 n (%)
Objectives of the training program were clearly defined and met 22 (95.6) 0 (0) 0 (0) 0 (0) 0 (0)
Content of the training were relevant to my practice 20 (86.9) 2 (8.6) 0 (0) 0 (0) 0 (0)
The training content was organized and easy to follow 20 (86.9) 2 (8.6) 0 (0) 0 (0) 0 (0)
On-line content was easy to use 20 (86.9) 1 (4.3) 1 (4.3) 0 (0) 0 (0)
On-line content was understandable 18 (78.3) 2 (8.6) 0 (0) 1 (4.3) 0 (0)
Time allocated for the training program was realistic and sufficient 20 (86.9) 1 (4.3) 1 (4.3) 0 (0) 0 (0)
The educational program improved my knowledge about CVD prevention
strategies
19 (82.6) 2 (8.6) 1 (4.3) 0 (0) 0 (0)
Hands-on training at the professional skills laboratory improved my skills 19 (82.6) 3 (13) 0 (0) 0 (0) 0 (0)
Lecturers are knowledgeable on CVD risk assessment and management 20 (86.9) 1 (4.3) 0 (0) 0 (0) 0 (0)
Lecturers communicated information clearly 21 (91.3) 1 (4.3) 0 (0) 0 (0) 0 (0)
The educational program has motivated me to participate in Phase 3 of the
study
21 (91.3) 1 (4.3) 0 (0) 0 (0) 0 (0)
Notes: A total of 23 pharmacists completed the satisfaction survey. n and % represent the number and percentage of pharmacists, respectively, that gave a specific response
to each of the statements.
Figure 2 Participants’ satisfaction with the educational program. Participants were administered a satisfaction survey at the conclusion of the educational program that was
graded on a 5-point scale (very satisfied, satisfied, neutral, dissatisfied and very dissatisfied). The height of the bars represents the number of respondents providing a given
rating.
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concepts about CVDRAM, such as the management of
dyslipidemia and blood pressure control. This improved
knowledge may provide pharmacists with increased con-
fidence to engage with patients for managing these impor-
tant risk factors. A study on the provision of
pharmaceutical care by community pharmacists reported
improved adherence to statin therapy with positive clinical
outcomes41 and on their counselling on lifestyle changes
and DASH diet helped patients lower their blood
pressure.42 Two of the three questions for which wrong
responses prevailed in the post-questionnaire (specifically
questions 1 and 2) were related to the CVDRAM guide-
lines. We speculate that the participants did not give much
importance to this content. Studies have shown that health-
care providers are generally unaware of guidelines.43
Complexity of guidelines, lack of resources and time are
other possible reasons why healthcare providers are not
using guidelines.44 Our future educational programs will
emphasize on guidelines and screening criteria for appar-
ently healthy adults that would be translated into practice.
Despite the fact that all participants passed the OCSE,
a low score was noted in the physical examination Station
1. This can be explained by two aspects. First, participants
may be reluctant to learn and apply physical assessment
skills in a community setting where the use of POC
devices is not fully supported by Qatar Ministry of
Public Health. Second, time to practice physical assess-
ment skills during the workshops could have been
insufficient. Thus, reassessing the course delivery for addi-
tional practice sessions or increased time for practice is
needed to improve participant performance in the future.
Compared to our previous study in which participating
pharmacists averaged a score of 38%, participants per-
formed well in the post-educational assessment. This
could be due to lack of sufficient knowledge as well as
unaware of being assessed during their community phar-
macy practice work hours where they could have been
busy with a series of customers and patients.
The educational program has also been positively eval-
uated by participating pharmacists, some of whom
reported reflections indicative of them being likely to
implement what was learnt into their practice settings.
This is consistent with findings in similar studies which
utilized courses with a blended-learning design to which
participants reported positive learning experiences and
high satisfaction ratings.39,45-47
Low sample size is a limitation of this study. However,
the aim of this study was to describe the educational
program and its potential application to pharmacy practice
in Qatar and elsewhere. Results of the course assessments
are informative and should be taken into consideration
when deciding the type of educational strategies that are
most suitable to deliver CPD programs to improve com-
petencies of community pharmacists in Qatar. Future itera-
tions of the course must more thoroughly evaluate all 4
levels of the Kirkpatrick’s evaluation framework, through
administration of in-depth interviews with previous parti-
cipants, their patients, and their managers.
Conclusions
Overall, the blended-learning educational program in
CVDRAM was well received and successful in improving
the knowledge and skills of the participating pharmacists.
It represents an important resource and a first step in
support of implementing access to CVDRAM services
within primary care in Qatar.
Data Sharing Statement
Data supporting the results reported in the manuscript are
currently securely stored in password-protected electronic
format but can be obtained from the researchers. The content
of the educational module described and evaluated herein is
not publicly available and it is considered intellectual prop-
erty of the researchers. Online access to the module is pass-
word protected. Access can be solicited to the researchers. No
other data than the one presented herein remain unpublished.
Table 4 Participants’ Selected Reflections on the Educational
Program
Reflections On Selected Comments†
OSCE “OSCE experience was great, we need
more practice to reach the ideal [practice]”
(Participant 1)
“OSCE was so much enlightening and
[relaxed]” (Participant 2)
Educational program “There was no bad thing [with the training
course] except that we need more
examples and more practice to confirm
what we have [learnt] but it was really an
amazing experience” (Participant 3)
Application in practice “I have better information now . . . and for
sure my whole daily work will get better”
(Participant 2)
“I am going to apply what I have learned”
(Participant 3)
Note: †Reflections provided by only those who participated in the OSCE.
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